Antiangiogenic therapy for dogs with any measurable cancer
Eligibility:
* Measurable disease defined by examination, radiographs or ultrasound
* No cytotoxic therapy within 3 weeks of trial initiation
* Prednisone or NSAID therapy permitted if introduced at least 3 weeks before trial initiation
* No previous antiangiogenic therapy
Antiangiogenic therapy for dogs with any measurable cancer
Trial Support: Study patients receive Thrombospondin-I peptide at no charge. Medical examinations and diagnostic tests needed to measure response are the responsibility of the owner. All cases must be evaluated and treated through the Animal Cancer Institute primary clinic site at Friendship Hospital for Animals, Washington DC. Diagnostic tests may be performed at any veterinary hospital within 10 days of initiation of study
Pet owners seeking novel treatment options for animals with serious health conditions find an Animal Clinical Investigation network veterinarian participating in a clinical trial.
Animal Clinical Investigation network veterinarian and pet owner work together to determine whether the pet is eligible for the trial. Eligible pets begin treatment at an ACI network hospital.
Information from the trial is used to help develop new drugs and treatments, providing a source of hope for people whose pets face serious illnesses.